A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 22 May 2019 Status changed from not yet recruiting to recruiting.
- 11 Feb 2019 Planned initiation date changed from 1 Dec 2018 to 1 Feb 2019.
- 13 Dec 2018 New trial record